Sugi Predict

Sugi Predict / Compounds / SCHEMBL19253537

SCHEMBL19253537

SCHEMBL19253537

COc1ccc(COc2nn(C)cc2B2OC(C)(C)C(C)(C)O2)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ UCHL1 P09936 1/20 0.46
▸ CNR2 P34972 4/20 0.43
▸ CNR1 P21554 3/20 0.43
▸ CSF1R P07333 3/20 0.38
▸ DGAT1 O75907 1/20 0.38
▸ HRH4 Q9H3N8 1/20 0.38
▸ BCHE P06276 1/20 0.38
▸ APP P05067 5/20 0.37
▸ GABRA1 P14867 1/20 0.36
▸ GABRG2 P18507 1/20 0.36
▸ GABRB3 P28472 1/20 0.36
▸ GABRA5 P31644 1/20 0.36
▸ GABRA3 P34903 1/20 0.36
▸ GABRA2 P47869 1/20 0.36
▸ ACHE P22303 1/20 0.36
▸ MAOB P27338 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23070575 0.86 DGAT1 (0.45) CNR2CNR1DGAT1HRH4ACHE
SCHEMBL23858552 0.79 UCHL1 (0.35) UCHL1
SCHEMBL23308756 0.78 UCHL1 (0.41) UCHL1CNR2CNR1DGAT1HRH4
SCHEMBL21872251 0.75 CNR2 (0.48) CNR2CNR1CSF1RHRH4BCHE
SCHEMBL19253516 0.74 APP (0.51) CNR2CNR1CSF1RHRH4BCHE
SCHEMBL12970586 0.74 PDE10A (0.38) DGAT1SMN1; SMN2
SCHEMBL20819186 0.74 ABCB1 (0.49) UCHL1CSF1RDGAT1APPMAOB
SCHEMBL2267580 0.72 DGAT1 (0.56) DGAT1APPMAOBSMN1; SMN2
SCHEMBL20138771 0.72 UCHL1 (0.65) UCHL1SMN1; SMN2
SCHEMBL15240775 0.72 UCHL1 (0.43) UCHL1CSF1RDGAT1APPMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12129256-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives PFIZER INC. (US) 2024-10-29 — — US disclosed
US-20230045252-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2023-02-09 — — US disclosed
US-20230045252-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2023-02-09 — — US disclosed
US-11472809-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives PFIZER INC. (US) 2022-10-18 — — US disclosed
US-11472809-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives PFIZER INC. (US) 2022-10-18 — — US disclosed
EP-3712153-B1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER (US) 2021-12-01 — — EP disclosed
EP-3712153-B1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER (US) 2021-12-01 — — EP disclosed
CN-109071546-B Pyrazolo [1,5-A ] pyrazin-4-yl derivatives as JAK inhibitors 辉瑞大药厂 2021-03-02 — — CN disclosed
US-20200399281-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2020-12-24 — — US disclosed
US-20200399281-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2020-12-24 — — US disclosed
EP-3419978-B1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER (US) 2020-04-15 — — EP disclosed
US-20190071448-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2019-03-07 — — US disclosed
US-20190071448-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2019-03-07 — — US disclosed
EP-3419978-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS Pfizer Inc (US) 2019-01-02 — — EP disclosed
US-10144738-B2 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives PFIZER INC. (US) 2018-12-04 — — US disclosed
WO-2017144995-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER INC. (US) 2017-08-31 — — WO disclosed
WO-2017144995-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER INC. (US) 2017-08-31 — — WO disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12129256-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives CBR3, CNR1, CBR1 UCHL1 4667/4885CNR2 11/4885CNR1 2/4885
US-20230045252-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 UCHL1 4603/4885CNR2 17/4885CNR1 2/4885
US-10144738-B2 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives JAK1, JAK2, JAK3 UCHL1 4754/4885CNR2 384/4885CNR1 184/4885
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 UCHL1 4603/4885CNR2 17/4885CNR1 2/4885
US-20200399281-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CBR1 UCHL1 4667/4885CNR2 11/4885CNR1 2/4885
US-20190071448-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 UCHL1 4603/4885CNR2 17/4885CNR1 2/4885
US-11472809-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives SYMPK, IL15, STAT6 UCHL1 4765/4885CNR2 2194/4885CNR1 2593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.